AT CELLCARTA WE ARE DEDICATED TO WORKING WITH OUR PARTNERS TO FURTHER THE LIMITLESS POTENTIAL OF PRECISION MEDICINE
As a global contract research organization (CRO) laboratory, we partner with our clients to address the most complex biomarker and bioanalytical challenges and deliver highly customized testing solutions. With facilities located in Canada, United States, Belgium, Australia and China, CellCarta provides the expertise needed locally to support global clinical trials.
CellCarta offers access to integrated analytical platforms in immunology (immune monitoring), histopathology, proteomics and genomics, as well as sample logistics services.
At CellCarta we are experts at assessing the immune system, whether in the context of oncology, infectious diseases, or autoimmune diseases. With a proven track record in other therapeutic areas as, such as neurological and metabolic disorders, we handle all human biological specimens and deploy relevant technologies to extract valuable information for research and diagnostic applications. We provide assay development and testing services to support a wide variety of translational research, clinical trials, and diagnostic applications.
Committed to delivering the highest quality science and innovation, CellCarta recently acquired Clinical Logistics to expand its specialty specimen logistics and kitting services and Mosaic Laboratories for multiplex immunohistochemistry assays development and deployment.
Reflecting our commitment to quality, our sites hold the appropriate accreditations to support your regulatory requirements, inNeo-Epitope Discoverycluding CAP, CLIA, ISO15189 and ISO13485.
CellCarta is privately held and majority-owned by Arsenal Capital Partners.